Treatment of Ibd and Ibs Using Both Probiotic Bacteria and Fermented Cereal as Treatment Effectors

Abstract

The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be an effecter. The novel treatment strategy is capable of removing the symptoms of inflammatory bowel diseases regardless of a mild, moderate or severe stage of the disease.

1 . A ready-to-use product for the treatment of a gastrointestinal disease selected from Inflammatory Bowel Disease (IBD), IBD-related disorders and Inflammatory Bowel Syndrome (IBS), said product comprising an effective amount of a composition comprising at least 0.05 g/ml (dry weight) fermented cereal and at least 1×10 8  cfu/ml of non-pathogenic microorganisms. 
     
     
         2 . A product according to  claim 1  comprising at least 0.1 g/ml (dry weight) fermented cereal and at least 1×10 9  cfu/ml of non-pathogenic microorganisms. 
     
     
         3 . A product according to  claim 1 , wherein the effective amount for one day's treatment is at least 10 g (dry weight) of said fermented cereal, and at least 5×10 10  cfu of said microorganisms. 
     
     
         4 . A product according to  claim 3 , wherein the product for one day's treatment comprises
 at least 10 g (dry weight) of said fermented cereal, and at least 5×10 10  cfu of said microorganisms,   preferably at least 18 g (dry weight) of said fermented cereal and at least 1×10 11  cfu of said microorganisms,   more preferably at least 36 g (dry weight) of said fermented cereal and at least 2×10 11  cfu of said microorganisms and   even more preferably at least 90 g (dry weight) of said fermented cereal and at least 5×10 11  cfu of said microorganisms.   
     
     
         5 . A product comprising at least 0.05 g/ml (dry weight) of a fermented cereal composition, at least 1×10 8  cfu/ml of non-pathogenic microorganisms, and added phospholipid, preferably phosphaditylcholine. 
     
     
         6 . A product according to  claim 5  for use in treatment of a gastrointestinal disease selected from Inflammatory Bowel Disease (IBD), IBD-related disorders and Inflammatory Bowel Syndrome (IBS). 
     
     
         7 . A product according to  claim 5 , wherein the product for one day's administration comprises at least 10 g (dry weight) of said fermented cereal, at least 5×10 10  cfu of said microorganisms and at least 0.1 g of said phospholipids, preferably at least 0.1 g phosphaditylcholine. 
     
     
         8 . A product according to  claim 7 , wherein the product for one day's administration comprises
 at least 10 g (dry weight) of said fermented cereal, and at least 5×10 10  cfu of said microorganisms,   preferably at least 18 g (dry weight) of said fermented cereal and at least 1×10 11  cfu of said microorganisms,   more preferably at least 36 g (dry weight) of said fermented cereal and at least 2×10 11  cfu of said microorganisms, and   most preferably at least 90 g (dry weight) of said fermented cereal and at least 5×10 11  cfu of said microorganisms.   
     
     
         9 . A product according to  claim 1 , wherein said cereal is fermented by one or more microorganisms capable of fermenting said cereal. 
     
     
         10 . A product according to  claim 9 , wherein said cereal is fermented by said one or more microorganisms present in the product. 
     
     
         11 . A product according to  claim 9 , wherein said one or more cereal fermenting microorganisms are selected from lactic acid bacteria, propionic acid bacteria and  Bifidobacterium  spp. 
     
     
         12 . A product according to  claim 9 , wherein said one or more microorganisms in the product is (are) added to the product after the fermentation. 
     
     
         13 . A product according to  claim 1 , wherein said one or more microorganisms are selected from  Carnobacterium, Enterococcus, Lactobacillus, Lactococcus, Leuconostoc, Oenococcus, Pediococcus  and  Streptococcus.    
     
     
         14 . A product according to  claim 13 , wherein said one or more microorganisms in the product is (are) anti-inflammatory inducing microorganisms (probiotics). 
     
     
         15 . A product according to  claim 14 , wherein said microorganisms are one or more intestine colonizing  Lactobacillus  and/or  Bifidobacterium  strains, for example  L. plantarum  299 and/or  L. plantarum  299v. 
     
     
         16 . A product according to  claim 1 , wherein the cereal is oat (oatmeal). 
     
     
         17 . A product according to  claim 1 , wherein said product for one day's administration is divided into at least two separate portions. 
     
     
         18 . A product according to  claim 1 , wherein said product essentially does not contain any milk or milk products or any easily fermentable sugars such as sucrose, lactose, glucose or fructose. 
     
     
         19 . A product according to  claim 1 , further comprising food or medical additives such as taste enhancers, colors, pH and osmosis-regulators, vitamins, herbs, herbal components, minerals, viscosity regulators, lipids, emulsifiers, glutamine and other amino acids, antioxidants, blood pressure regulators, pain relief substances. 
     
     
         20 . A product according to  claim 1 , further comprising an additional active agent suitable for treatment of gastrointestinal disorders or other diseases. 
     
     
         21 . A product according to  claim 1 , in the form of a drinkable, eatable, anally administrable or tube administrable product. 
     
     
         22 . A ready-to-use product for treatment of IBD, IBD-related disorders and IBS comprising:
 at least 0.05 g/ml (dry weight) fermented cereal and at least 1×10 8  cfu/ml of non-pathogenic microorganisms.   preferably at least 0.1 g/ml (dry weight) fermented cereal and at least 1×10 9  cfu/ml of non-pathogenic microorganisms.   
     
     
         23 . The product according to  claim 22 , wherein said effective amount for one days treatment comprises
 at least 10 g (dry weight) of said fermented cereal, and at least 5×10 10  cfu of said microorganisms,   preferably at least 18 g (dry weight) of said fermented cereal and at least 1×10 11  cfu of said microorganisms,   more preferably at least 36 g (dry weight) of said fermented cereal and at least 2×10 11  cfu of said microorganisms, and   even more preferably at least 90 g (dry weight) of said fermented cereal and at least 5×10 11  cfu of said microorganisms.   
     
     
         24 . Use according to  claim 22 , wherein said product further comprises phospholipids, preferably phosphaditylcholine. 
     
     
         25 . The product according to  claim 24 , wherein said product for one day's treatment comprises at least 0.1 g phospholipid, preferably at least 0.1 g phosphaditylcholine. 
     
     
         26 . The product according to  claim 22 , wherein the cereal is oat (oatmeal). 
     
     
         27 . The product according to  claim 22 , wherein said cereal is fermented by said microorganisms. 
     
     
         28 . The product according to  claim 22 , wherein said microorganisms is one or more intestine colonizing  Lactobacillus  spp or  Bifidobacterium  spp., for example  L. plantarum  299 and/or  L. plantarum  299v. 
     
     
         29 . The product according to  claim 22 , wherein said product essentially does not comprise any milk or milk products and essentially does not contain any easily fermentable sugars such as sucrose, lactose, glucose or fructose. 
     
     
         30 . The product according to  claim 22 , wherein said microorganisms in said product are not freeze or spray dried. 
     
     
         31 . The product according to  claim 22 , wherein said product prepared for one day's treatment is divided into at least two separate portions. 
     
     
         32 . A method for treating IBD, IDB-related disorders or IBS, which comprises administering daily to a patient in need of such treatment an of a ready-to-use product of comprising at least 100 ml of a composition which comprises at least 0.05 g/ml (dry weight) fermented oat meal and at least 1×10 8  cfu/ml of  Lactobacillus  spp or  Bifidobacterium  spp. 
     
     
         33 . The method according to  claim 32 , wherein said product comprises at least 200 ml of said composition. 
     
     
         34 . The method according to  claim 32 , wherein said composition comprises at least 0.1 g/ml (dry weight) fermented oat meal and at least 1×10 9  cfu/ml of said  Lactobacillus  spp or  Bifidobacterium  spp. 
     
     
         35 . The method according to  claim 32 , wherein said  Lactovacillus  spp. Is  L. plantarum  299 and/or  L. plantarum  299v. 
     
     
         36 . The method according to  claim 32 , wherein the product in comprises at least 0.1 g phosphaditylcholine. 
     
     
         37 . The method according to  claim 32 , wherein said product is essentially devoid of any milk or milk products and any easily fermentable sugars such as sucrose, lactose, glucose and fructose. 
     
     
         38 . The method according to  claim 32  which comprises administering said product twice a day to the patient.